araag2/HINT huggingface dataset:
Clinical trial NCT00520780 (phase 3, status: completed)
Conditions: chronic heart failure, iron deficiency, iron deficiency anemia, anaemia
ICD codes: I50.812, I50.22, I50.32, I50.813, I50.23, I50.33, I50.42, E61.1, D50.8, D50.9, D50.0, D50.9, D50.0, D50.8
Drugs: ferinject ® (ferric carboxymaltose), normal saline (0.9%)
SMILES: C[C@@H]1O[C@@H]1P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  In New York Heart Association (NYHA) II-III functional class due to stable symptomatic
             chronic heart failure (CHF)

          -  Left ventricular ejection fraction (LVEF) 40% or lower for patients in NYHA II and 45%
             or lower in NYHA III

          -  Screening haemoglobin (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL (average
             of 2 haemoglobin concentrations)

          -  Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation
             (TSAT) is below 20%

        Exclusion Criteria:

          -  History of acquired iron overload.

          -  Known active infection, clinically significant bleeding, active malignancy.

          -  Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate
             transaminase (AST)

          -  Anaemia due to reasons other than iron deficiency

          -  Immunosuppressive therapy or renal dialysis (current or planned within the next 6
             months).

          -  History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in
             previous 12 weeks and/or such therapy planned within the next 6 months.

          -  Unstable angina pectoris as judged by the investigator, clinically significant
             uncorrected valvular disease or left ventricular outflow obstruction, obstructive
             cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly
             controlled symptomatic brady- or tachyarrhythmias.

          -  Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or
             stroke within the last 3 months.

          -  Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac,
             cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including
             thoracic and cardiac surgery, within the last 3 months.
Clinical trial NCT00351884 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin am, vildagliptin pm, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients on metformin for at least three months and on a stable dose of at least 1500
             mg daily for a minimum of 4 weeks prior to visit 1

          -  Body mass index in the range 22-40

          -  Blood glucose criteria must be met

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  History of type 1 diabetes

          -  Evidence of significant diabetic complications

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00034749 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects will be eligible for study enrollment if they: are adolescents between the
             ages of 13 and 17 years

          -  have a confirmed diagnosis of schizophrenia and are suffering from an acute episode

          -  provide their assent and parental informed consent to participate

          -  are otherwise relatively healthy on the basis of a medical and physical examination

          -  and are able to be in-patients for approximately 2 weeks.

        Exclusion Criteria:

          -  Subjects will be excluded from the study if they: meet the criteria for psychiatric
             disorders other than schizophrenia

          -  have moderate or severe mental retardation

          -  fail to respond to treatment with at least two typical or atypical antipsychotics

          -  have a history of substance dependence within the 3 months before screening

          -  are considered at risk for suicidal or violent behavior

          -  have a seizure disorder

          -  have a history of neuroleptic malignant syndrome, similar encephalopathic syndrome, or
             tardive dyskinesia

          -  or receive prohibited medication within a specified period before screening.
Clinical trial NCT01008995 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: placebo, ustekinumab, placebo, ustekinumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must be of Chinese ancestry

          -  Have had a diagnosis of plaque-type psoriasis at least 6 months prior to study start

          -  Have plaque-type psoriasis covering at least 10% of total BSA at screening and at the
             time of study start

          -  Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater at study start

          -  Must be candidates for phototherapy or systemic treatment of psoriasis (either naive
             or history of previous treatment)

        Exclusion Criteria:

          -  Currently have nonplaque forms of psoriasis

          -  Have current drug-induced psoriasis

          -  Have used any investigational drug within the previous 4 weeks

          -  Have used any biologic within the previous 3 months

          -  Be known to be infected with human immunodeficiency virus (HIV), hepatitis B virus
             (HBV), hepatitis C virus (HCV), or syphilis
Clinical trial NCT01033760 (phase 3, status: completed)
Conditions: hiv-1 infections
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine, darunavir; ritonavir; emtricitabine/tenofovir
SMILES: CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with acute or primary HIV-1 infection

          -  Acute infection: negative or slightly positive Elisa, with negative or incomplete
             western-blot (0 or 1 antibody) and positive HIV-RNA and/or positive Ag p24.

          -  Primary infection: positive Elisa with incomplete Western-blot (≥ 2 and < 5 antibodies
             with the presence of anti-p24 antibodies associated with an anti-gp160 or an
             anti-gp120 or an anti-gp41antibody) and positive HIV-RNA.

          -  Symptomatic Primary infection or CD4 <500/mm3

          -  written informed consent

          -  ≥ 18 years old

        Exclusion Criteria:

          -  Prior post exposure antiretroviral treatment within six months before enrolment

          -  Pregnancy or breast-feeding

          -  HIV-2 infection

          -  Current malignancy

          -  Prothrombin time < 50%

          -  Creatinine clearance < 60 ml/min

          -  ASAT, ALAT or bilirubin ≥10*N

          -  Platelets < 25000/mm3
Clinical trial NCT01181167 (phase 3, status: completed)
Conditions: prevention, venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: edoxaban, enoxaparin sodium
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Patients undergoing unilateral total hip arthroplasty

        Exclusion Criteria:

          -  Subjects with risks of hemorrhage

          -  Subjects with thromboembolic risks

          -  Subjects who weigh less than 40 kg

          -  Subjects who are pregnant or suspect pregnancy, or subjects who want to become
             pregnant
Clinical trial NCT00729430 (phase 3, status: completed)
Conditions: myocardial infarction, death, sudden, cardiac
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: omega-3 fatty acids (fish oil supplements), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Experienced a heart attack in the 2 to 4 weeks before study entry

          -  Lives in the greater Boston area or adjacent regions (within a 50-mile radius of
             Boston)

        Exclusion Criteria:

          -  Unable to undergo an MRI because of metallic implants (e.g., pacemakers, an
             implantable cardioverter defibrillator [AICD]) at time of study entry

          -  Active cancer or any other terminal illness with an expected survival rate of less
             than 6 months after study entry

          -  Significant kidney dysfunction with a glomerular filtration rate (GFR) of less than 60
             mL/min in the 2 weeks before study entry

          -  Inability to follow study procedures

          -  Pregnant

          -  Hemodynamic instability

          -  Urgent clinical need for a pacemaker or AICD

          -  Inaccessibility of medical records
Clinical trial NCT01654250 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: nwp09, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this
             condition

        Exclusion Criteria:

          -  Other serious illnesses or conditions that would put the patient at particular risk
             for safety events or would interfere with treatment/assessment of ADHD
Clinical trial NCT00573001 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: tenofovir/emtricitabine (truvada) and nevirapine, tenofovir/emtricitabine/efavirenz (atripla), tenofovir (viread) and lopinavir/ritonavir (aluvia), tenofovir/emtricitabine (truvada) and zidovudine
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  age over 18 years for Senegal and over 21 years for Cameroon

          -  HIV-1 infected patient

          -  patient naive from any antiretroviral treatment

          -  CD4 cell count over 50 cells per mm3

          -  contraceptive method use

          -  informed consent signed

        Exclusion Criteria:

          -  opportunistic infection ongoing or any other serious pathology

          -  ongoing treatment with rifampicine

          -  severe renal or hepatic impairment

          -  HbSAg positive

          -  Hemoglobine under 8g/L

          -  Neutrophils under 500 cells per mm3

          -  ongoing pregnancy or breastfeeding

          -  treatment by contra-indicated drugs (as described in study drugs notices)
Clinical trial NCT00471497 (phase 3, status: completed)
Conditions: myelogenous leukemia, chronic
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: nilotinib, imatinib
SMILES: CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Key Inclusion criteria:

          -  Chronic myelogenous leukemia in chronic phase patients within the first 6 months of
             diagnosis.

          -  Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of
             Philadelphia chromosome of (9:22) translocations

        Key Exclusion criteria:

          -  Previously documented T315I mutation

          -  Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except
             for no more than 2 weeks in duration of imatinib

          -  Any medical treatment for CML prior to study entry for longer than 2 weeks with the
             exception of hydroxyurea and/or anagrelide

          -  Impaired cardiac function.

          -  Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or
             uncontrolled infection).

          -  Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)

          -  Currently receiving treatment with any medications that have the potential to prolong
             the QT interval.
Clinical trial NCT00390806 (phase 3, status: completed)
Conditions: lung cancer, non-small cell
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: hycamtin, oral capsules
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion criteria:

          -  At least one measurable cancerous lesion in the brain from primary non-small cell lung
             cancer (NSCLC)

          -  Must have received previous chemotherapy

          -  Must be 18 years of age of greater

          -  Must be Easter Cooperative Oncology Group (ECOG) Performance Status 0, 1, 2

          -  At least 2 weeks must have elapsed since any surgery

          -  At least 4 weeks must have elapsed since any radiation to a non-CNS site

          -  Must have adequate bone marrow, renal, and live capacities

          -  Women must be of non-childbearing potential or practice adequate birth control

          -  Males must practice adequate methods of birth control

          -  Must sign written informed consent

        Exclusion criteria:

          -  Previous whole brain radiation therapy

          -  Prior treatment with topotecan

          -  Investigational agent within 30 days or 5 half-live

          -  Concomitant therapy with inhibitors of breast cancer resistance protein (BCRP) or
             P-glycoprotein such as erlotinib or gefitinib

          -  Primary or secondary immunodeficiencies

          -  Gastrointestinal conditions that affect GI absorption or motility

          -  Uncontrolled emesis

          -  Brain metastasis at time of initial diagnosis of NSCLC

          -  History of other malignancy except in situ carcinoma of cervix; nonmelanomatous skin
             cancer, low grade prostate cancer

          -  Pregnant or intending to become pregnant or intending to father a baby

          -  Any severe concurrent medical condition that could affect compliance.
Clinical trial NCT01256177 (phase 3, status: completed)
Conditions: bipolar depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: quetiapine fumarate (seroquel) extended release, placebo
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Male and female patients, aged 18 to 65 years, inclusive.

          -  Meets Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV)
             criteria for bipolar disorder I or bipolar II, most recent episode depressed (296.5x
             and 296.89x).

          -  Hamilton Rating Scale for Depression (HAM-D) (17-item) total score of ≥ 20 and HAM-D
             item 1 (depressed mood) score ≥ 2 at enrolment and randomisation.

          -  Patients must be able to understand and comply with the requirements of the study,as
             judged by the Investigator

        Exclusion Criteria:

          -  Patients with a current Diagnostic and Statistical Manual of Mental Disorders - 4th
             Edition (DSM-IV) diagnosis other than bipolar disorder

          -  Patients whose Young Mania Rating Scale (YMRS) total score >12 at enrolment and
             randomisation.

          -  Patients with >8 mood episodes during the past 12 months at enrolment.

          -  Patients whose current episode of depression exceeds 12 months or is less than 4 weeks
             from enrolment.

          -  Patients with a history of non-response to an adequate treatment (6 weeks) with more
             than 2 classes of antidepressants during their current episode.

          -  Alcohol or other substance dependence or abuse as defined by Diagnostic and
             Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) criteria at enrolment
             that is not in extended full or extended partial remission (12 months or longer),
             except caffeine and nicotine dependence.

          -  Patients who, in the Investigator's judgment, pose a current serious suicidal or
             homicidal risk, have a Hamilton Rating Scale for Depression (HAM-D) item 3 score ≥ 3,
             or have made a suicide attempt within the past 6 months.
Clinical trial NCT00729469 (phase 3, status: completed)
Conditions: atrophy, vaginal diseases
ICD codes: H21.29, H31.23, H47.20, H47.22, N50.0, N64.2, N90.5
Drugs: ospemifene 60 mg, placebo
SMILES: OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Naturally or surgically menopausal

          -  Moderate or severe symptoms of vaginal atrophy

          -  5% or fewer superficial cells in maturation index of vaginal smear

          -  Vaginal pH greater than 5.0

          -  Self reported Most Bothersome Symptom of vaginal dryness or vaginal pain associated
             with sexual activity, with a severity of moderate or severe at randomization

        Exclusion Criteria:

          -  Uterine bleeding of unknown origin, uterine polyps or symptomatic and/or large uterine
             fibroids

          -  Current vaginal infection requiring medication

          -  Clinically significant abnormal gynecological findings other than signs of vaginal
             atrophy (e.g.

        uterine or vaginal prolapse of Grade 2 or higher)

          -  Previous participation in any other ospemifene study
Clinical trial NCT00631475 (phase 3, status: completed)
Conditions: idiopathic pulmonary fibrosis
ICD codes: J84.112
Drugs: bosentan
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

        Patients should have completed all the assessments from the BUILD 3 (NCT00391443) end of
        study (EOS) visit.

          -  Signed informed consent prior to initiation of any study-related procedures.

          -  Women of childbearing potential must have a negative serum pregnancy test and use
             reliable methods of contraception during study treatment and for 3 months after study
             treatment termination.

        Exclusion Criteria:

          -  Any major violation of protocol AC-052-321 / BUILD 3 (NCT00391443).

          -  Pregnancy or breast-feeding.

          -  AST and/or ALT > 3 times the upper limit of the normal range.

          -  Any known factor or disease that might interfere with treatment compliance, study
             conduct or interpretation of the results, such as drug or alcohol dependence or
             psychiatric disease.

          -  Known hypersensitivity to bosentan or any of the excipients.
Clinical trial NCT00431106 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: gemcitabine, capecitabine, vinorelbine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Age 19-75 years.

          -  Performance status World Health Organization (WHO) 0-2.

          -  Histologically confirmed breast adenocarcinoma.

          -  Clinical or radiological evidence of metastatic disease that has progressed after
             combination treatment of a taxane and an anthracycline (Taxotere + Mitoxantrone or
             Taxotere + Farmorubicine).

          -  Measurable disease.

          -  No metastatic central nervous system (CNS) disease.

          -  Less than 25% of myeloproductive bone marrow irradiated.

          -  Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count >
             100000/mm^3, hemoglobin > 9 gr/mm^3).

          -  Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times
             upper limit of normal) and renal function (creatinine < 2 mg/dl).

          -  Informed consent.

        Exclusion Criteria:

          -  Pregnancy or nursing.

          -  Positive pregnancy test.

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Other invasive malignancy within the past 5 years except nonmelanoma skin cancer.
Clinical trial NCT00490035 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: brivaracetam, brivaracetam, brivaracetam
SMILES: CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects were from 16 to 70 years, both inclusive. Subjects under 18 years of age were
             only included where legally permitted and ethically accepted

          -  Subjects with well-characterized focal epilepsy or epileptic syndrome according to the
             International League Against Epilepsy (ILAE) classification

          -  Subjects had a history of partial onset seizures (POS) whether or not secondarily
             generalized (Type I seizures according to the ILAE classification)

          -  Subjects had at least 2 POS whether or not secondarily generalized per month during
             the 3 months preceding Visit 1

          -  Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week
             Baseline Period

          -  Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic
             drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant
             AED

        Exclusion Criteria:

          -  History or presence of seizures occurring only in clusters (too frequently or
             indistinctly separated to be reliably counted) before Visit 3

          -  History or presence of status epilepticus during the year preceding Visit 1 or during
             Baseline